Nuveen Asset Management, LLC Point Biopharma Global Inc. Transaction History

Nuveen Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.67 - $9.71 $750,701 - $1.09 Million	-112,549 Reduced 10.16%	995,217 $6.64 Million
Q2 2023 Aug 14, 2023	BUY	$6.86 - $10.86 $4.6 Million - $7.28 Million	670,732 Added 153.47%	1,107,766 $10 Million
Q1 2023 May 15, 2023	BUY	$6.78 - $8.1 $159,316 - $190,333	23,498 Added 5.68%	437,034 $3.18 Million
Q4 2022 Feb 14, 2023	BUY	$5.72 - $9.78 $860,425 - $1.47 Million	150,424 Added 57.17%	413,536 $3.01 Million
Q3 2022 Nov 14, 2022	SELL	$7.24 - $10.31 $14,733 - $20,980	-2,035 Reduced 0.77%	263,112 $2.03 Million
Q2 2022 Aug 15, 2022	BUY	$5.6 - $9.5 $1.25 Million - $2.12 Million	223,330 Added 534.07%	265,147 $1.81 Million
Q1 2022 May 16, 2022	BUY	$5.46 - $8.13 $228,320 - $339,972	41,817 New	41,817 $271,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.